Join our newsletter
Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot.
EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox
PROVIDENCE, RI, June 10, 2022 /PRNewswire/ --...
EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever
PROVIDENCE, RI, May 25, 2022 /PRNewswire/ --...
EpiVax Partners with Rhode Island Foundation to Expand Charitable Giving Programs
PROVIDENCE, RI, February 8, 2022 /PRNewswire/ --...
EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants
PROVIDENCE, RI, November 30, 2021 /PRNewswire/...
EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology
PROVIDENCE, RI, November 2021 /PRNewswire/ --...
EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition
PROVIDENCE, RI, November 4, 2021 /PRNewswire/ --...
Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax
PROVIDENCE, RI, July 6, 2021 /PRNewswire/ --...
EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ --...
Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics’ Ancer Platform
PROVIDENCE, RI, May 13, 2021 /PRNewswire/ --...
EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology
PROVIDENCE, RI, April 27, 2021 /PRNewswire/ --...
EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)
PROVIDENCE, RI, February 17, 2021 /PRNewswire/...
EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19
PROVIDENCE, R.I., Dec. 31, 2020 /PRNewswire/ --...